Article
Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation.
Cancer gene therapy - 1 Sept 2017
Lai J-I, Lai Y-C, Chen Y-C, Wang N-K, Pan J-N, Wang W-S, Chang S-C
Abstract excerpt
Lung cancer is one of the leading causes of death from cancer worldwide, with a poor prognosis in advanced cases. In the past decade, epidermal growth factor receptor (EGFR) inhibitors have shown significant efficacy towards treatment for EGFR mutant lung cancer. Expanding our knowledge of oncogenic EGFR signaling pathways is therefore of highly importance for the cancer field. Recently it has been proposed that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.